The Hebrew University holds a staggering number of nearly ten thousand patents and over 100 spun-off products. Below is a modest selection of just three of Yissum’s “golden egg” success stories.
Exelon is an Acetylcholinesterase inhibitor, a type of medicine prescribed for people in the early or middle stages of Alzheimer’s disease.
Exelon was invented by Prof. Marta Weinstock-Rosin from the Hebrew University and was developed and commercialized by Novartis with annual sales of 1 Billion. Though not a cure, Exelon has been shown to be an effective medicine for treating the symptoms of mild to moderate Alzheimer’s disease. Prof. Weinstock-Rosin is also the inventor of Ladostigil, the Phase II product of Avraham Pharma, one of Integra Holdings’ advanced stage companies.
Doxil is a PEGylated lyposomal Doxorubicin, a targeted drug for cancer therapy. Doxyl was invented by
Prof. Yechezkel Barenholtz and Prof. Alberto Gabizon from the Hebrew University and was developed and commercialized by Johnson & Johnson with annual sales of over $900 million. Doxil is indicated for the treatment of CisPt resistant ovarian cancer patients, Kaposi Sarcoma patients and third-line breast cancer patients.
Prof. Barenholtz is the founder and chief scientist of Ayana and Lipocure, and Prof. Gabizon is the founder and CEO of Lipomedix, all of which are Integra portfolio companies.
Mobileye has developed unique vision-based advanced driver assistance systems (ADAS) providing warnings for collision prevention and mitigation. The company’s proprietary chips have been successfully installed in millions of vehicles worldwide and the technology was selected for implementation in the serial production of
237 car models from 20 OEMs by 2016.
NYSE: MBLY- raised $1.023 billion – a record IPO for an Israeli company.
In March 2017, Intel acquired Mobileye for $15.3 billion, the largest-ever deal in the Israeli high-tech industry.
Prof. Shaashua from the Computer Sciences & Engineering Faculty of Science, is the founder and the CEO of Mobileye.